Patients with CKD, defined by at least two abnormal estimated glomerular filtration rate (eGFR) or urinary albumin/creatinine ratio (UACR) measurements ≥90 days apart during 2019–2020, were followed until May 2023 utilizing electronic health records. This evidence concerns the gene ALB and chronic kidney disease.